SIMI, LISA
 Distribuzione geografica
Continente #
NA - Nord America 2.375
EU - Europa 2.013
AS - Asia 278
AF - Africa 3
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 4.671
Nazione #
US - Stati Uniti d'America 2.371
PL - Polonia 1.224
IT - Italia 172
IE - Irlanda 165
SE - Svezia 157
HK - Hong Kong 120
DE - Germania 82
UA - Ucraina 64
CN - Cina 58
CH - Svizzera 50
JO - Giordania 42
FI - Finlandia 40
IN - India 19
VN - Vietnam 19
GB - Regno Unito 16
FR - Francia 12
AT - Austria 11
TR - Turchia 11
SG - Singapore 9
BE - Belgio 7
CA - Canada 4
ES - Italia 4
NL - Olanda 4
SC - Seychelles 3
RO - Romania 2
AU - Australia 1
BY - Bielorussia 1
EE - Estonia 1
EU - Europa 1
RU - Federazione Russa 1
Totale 4.671
Città #
Warsaw 1.224
Fairfield 396
Chandler 259
Ashburn 230
Woodbridge 179
Seattle 172
Dublin 165
Cambridge 155
Houston 142
Wilmington 134
Jacksonville 107
Hong Kong 84
Altamura 60
Ann Arbor 58
Lawrence 58
Florence 56
Bern 49
Princeton 47
Boardman 34
Boston 30
Beijing 27
New York 24
Buffalo 19
Bremen 18
Medford 18
Dong Ket 17
Pune 17
San Diego 17
Shanghai 14
Vienna 11
Izmir 10
Falls Church 9
Norwalk 9
Brussels 7
Milan 7
Phoenix 7
Hillsboro 6
Redwood City 6
Singapore 6
Auburn Hills 4
Barcelona 4
Fuzhou 4
Verona 4
Andover 3
Detroit 3
Frankfurt Am Main 3
Reggio Calabria 3
Salerno 3
Toronto 3
Arezzo 2
Dearborn 2
Dordrecht 2
Fontebuona 2
Kilburn 2
Nanchang 2
Nanjing 2
Pisa 2
Portland 2
Scandicci 2
Trumbull 2
Washington 2
Afa 1
Baotou 1
Botosani 1
Caserta 1
Chengdu 1
Harker Heights 1
Hefei 1
Helsinki 1
Hyderabad 1
Jinan 1
Kunming 1
Lachine 1
Latina 1
London 1
Mcallen 1
Modena 1
Mountain View 1
New Bedfont 1
Nürnberg 1
Old Bridge 1
Padova 1
Palermo 1
Provo 1
Radcliffe 1
Redmond 1
Sanayi 1
Santa Barbara 1
Sesto Fiorentino 1
Shaoxing 1
Tappahannock 1
Tartu 1
Tullamarine 1
Venezia 1
Yiwu 1
Totale 3.980
Nome #
Genetic variants in miR-146a, miR-149, miR-196a2, miR-499 and their influence on relative expression in lung cancers 256
Influence of 17q gain and promoter polymorphisms on mRNA expression of somatostatin receptor type 2 in neuroblastoma. 231
SPIDIA-DNA: an External Quality Assessment for the pre-analytical phase of blood samples used for DNA-based analyses. 202
SPIDIA-RNA: second external quality assessment for the pre-analytical phase of blood samples used for RNA based analyses. 201
Simultaneous measurement of MMP9 and TIMP1 mRNA in human non small cell lung cancers by multiplex real time RT-PCR. 201
High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. 200
Seladin-1 expression is regulated by promoter methylation inadrenal cancer 197
null 196
KIT genetic alterations in anorectal melanomas. 196
Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer 165
Association between single nucleotide polymorphisms in the XRCC1 and RAD51 genes and clinical radiosensitivity in head and neck cancer. 124
Denosumab treated giant cell tumour of bone: A morphological, immunohistochemical and molecular analysis of a series 105
Expression of uteroglobin and matrix metalloproteinase-9 genes in endometrial cancer: relationship to estrogen and progesterone receptor status. 101
Alternative splicing variants of carbonic anhydrase IX in human non-small cell lung cancer. 99
SPIDIA-RNA: First external quality assessment for the pre-analytical phase of blood samples used for RNA based analyses. 98
RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 97
Atypical Spitzoid melanocytic tumors: a morphological,mutational, and FISH analysis 96
An Italian Program of External Quality Control for Quantitative Assays Based on Real-Time PCR with Taq-Man Probes. 94
Measurement of somatostatin receptor subtype 2 mRNA in breast cancer and corresponding normal tissue 94
Tankyrase, a positive regulator of telomere elongation, is over expressed in human breast cancer. 92
GM1 gangliosidosis: molecular analysis of nine patients and development of an RT-PCR assay for GLB1 gene expression profiling. 92
Uncommon clinical presentations of pheochromocytoma and paraganglioma in two different patients affected by two distinct novel VHL germline mutations 91
Monitoring the susceptibility to oseltamivir of Influenza A(H1N1) 2009 virus by nested-PCR and pyrosequencing during the pandemic and in the season 2010-2011. 91
Quantitative analysis of carbonic anhydrase IX mRNA in human non-small cell lung cancer. 88
Phenotype variability of neural crest-derived tumours in six Italian families segregating the same founder SDHD mutation Q109X. 87
Histone 3.3 mutations in giant cell tumor and giant cell-rich sarcomas of bone. 86
Fluoropyrimidine-related toxicity in gastrointestinal cancer patients. Assessment of risk factors. 84
Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection. 82
Implementation of a companion diagnostic in the clinical laboratory: The BRAF example in melanoma 82
Metalloproteinases-2, -9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI. 82
BRAFV600E detection in melanoma is highlyimproved by COLD-PCR. 82
Atypical Spitzoid melanocytic tumors: a morphological, mutational, and FISH analysis. 79
Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma. 78
BRAF and KIT somatic mutations are present in amelanotic melanoma. 75
SDH mutations in patients affected by paraganglioma syndromes: a personal experience. 73
Unbalanced GLA mRNAs ratio quantified by real-time PCR in Fabry patients' fibroblasts results in Fabry disease. 68
Protective effect of TGFß3 on the irradiated small instestine of mice. 53
Antineoplastic effects of rosiglitazone and PPARgamma transactivation in neuroblastoma cells 53
Clodronate acts on human osteoclastic cell proliferation, differentiation and function in a bioreversible manner 53
From clinical trials to clinical practice: predictors ofresponse to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy 49
Uterine leiomyosarcomas express KIT protein but lack mutation(s) in exon 9 ofc-KIT. 45
Two novel H-RAS mutations identified in a child with anatypical spitzoid tumor. 30
The clinical role of PIK3CA mutations in colorectal cancer 29
Genetic variants in miR-146a, miR-149, miR-196a2, miR-499 and their influence on relative expression in lung cancers. 27
Early changes in circulating tumor DNA (ctDNA) predict treatment response in metastatic KRAS-mutated colorectal cancer (mCRC) patients 11
Totale 4.715
Categoria #
all - tutte 11.139
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.139


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019399 0 0 0 0 0 0 0 0 0 81 179 139
2019/20201.088 92 103 39 84 123 120 103 145 105 62 96 16
2020/2021733 52 66 43 125 56 83 27 56 56 87 36 46
2021/2022322 16 25 48 3 12 19 17 15 18 12 59 78
2022/2023981 72 198 39 98 67 162 105 51 98 4 22 65
2023/2024320 5 32 49 9 24 70 26 102 3 0 0 0
Totale 4.715